Manifestaciones cutáneas de la esclerodermiaun reto terapeútico

  1. Salazar Nievas, María
  2. Orgaz Molina, Jacinto
  3. Girón Prieto, M.S.
  4. Espiñeira Carmona, M. J.
  5. Gutiérrez Salmerón, María Teresa
Journal:
Actualidad médica

ISSN: 0365-7965

Year of publication: 2011

Tome: 96

Issue: 783

Pages: 30-37

Type: Article

DIALNET GOOGLE SCHOLAR HANDLE: https://hdl.handle.net/10481/36434

More publications in: Actualidad médica

Digibug. Repositorio Institucional de la Universidad de Granada: lock_openOpen access Handle

Sustainable development goals

Abstract

Scleroderma is a chronic and multisystemic connective tissue disease with high morbidity and mortality and unknown pathogenesis. The main symptoms are a result of collagen deposition and endothelial damage at heart, lung, gastrointestinal tract, kidney and skin. The skin involvement can become disabling and markedly worsen the quality of life of patients. The present article reviews the main cutaneous manifestations of this disease, its diagnosis and treatment options.

Bibliographic References

  • Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford). 2004;43:596–602.
  • Balaban EP, Sheehan RG, Lipsky PE, et al. Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. Ann Intern Med 1987; 106:56–8.
  • Clements P, Khanna D, Burger C, et al. Rapamycin (rapa) vs methotrexate (mtx) in early diffuse systemic sclerosis (ssc): a 48-week randomized, singleblind pilot safety study. ACR Annual Meeting 2006 Presentation number 1257.
  • Clements PJ, Furst DE, Wong WK, et al. Highdose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194–203.
  • Cukierman T, Elinav E, Korem M, et al. Low dose warfarin treatment for calcinosis in patients with systemic sclerosis.. Ann Rheum Dis. 2004;63:1341-3.
  • Denton CP, Sweny P, Abdulla A, et al. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994;33:90–2.
  • Dutz J. Treatment Options For The Cutaneous Manifestations Of Systemic Sclerosis. Skin Therapy Lett. 2000;6(1):3-5.
  • Gorlova O, Martin JE, Rueda B et al. Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genet. 2011;7:e1002178.
  • Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29:2371–8.
  • Herrgott I, Riemekasten G, Hunzelmann N et al. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. Rheumatol Int. 2008;28:1023-9.
  • Herrick A. Diagnosis and Management of Scleroderma Peripheral Vascular Disease. Rheum Dis Clin North Am. 2008; 34: 89-114.
  • Hoedkliniek D. Comparison of Methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364-72.
  • Knobler RM, French LE, Kim Y, et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006;54:793–9.
  • Korn JH, M. Mayes M, Matucci Cerinic M, et al. Digital Ulcers in Systemic Sclerosis Prevention by Treatment With Bosentan, an Oral Endothelin Receptor Antagonist. Arthritis & Rheumatism. 2004; 50:3985–3993.
  • Kyung Ream Han, Chan Kim, Eun Jung Park. Successful Treatment of Digital Ulcers in a Scleroderma Patient with Continuous Bilateral Thoracic Sympathetic Block. Pain Physician. 2008;11:91-6.
  • Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin: a preliminary report. ClinRheumatol 2000; 19:207–11.
  • Matucci-Cerinic M, J Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology 2008; 47: 46–v47
  • Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis–a retrospective analysis. Rheumatology 2007;46:442–5.
  • Nihtyanova SI, MBBS, Denton CP. Current Approaches to the Management of Early Active Diffuse Scleroderma Skin Disease. Rheum Dis Clin North Am. 2008;34:161-79.
  • Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351–8.
  • Postlethwaite AE, Furst DE, Wong WK, et al. Oral tolerance (OT) induction to type I collagen (CI) significantly reduces the skin score in patients with diffuse systemic sclerosis (SSc) with late-phase disease. Results of a NIAMS/NIAID multicenter phase II placebo controlled double blind clinical trial [abstract]. ACR Annual Meeting 2005 Presentation number L28.
  • Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis. 2003;62:267-9.
  • Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo controlled trial. Ann Intern Med. 2000;132:871–9.
  • Sevdalina Lambova, Ulf Müller-Ladne Lambova, Müller-Ladner, U. Treatment of digital ulcers in systemic sclerosis. Nat. Rev. Rheumatol. 2011; 7: 5–6.
  • Sfikakis PP, Gorgoulis VG, Katsiari CG et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008;47:735-7.
  • Sparsa A, Lesaux N, Kessler E, et al. Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol. 2005; 53:S263-5.
  • Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
  • Tehlirian CV, Hummers LK, White B, et al. High dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis. 2008 Jun;67(6):775-81.
  • Vayssairat M, Hidouche D, Abdoucheli-Baudot N, et al. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression?. Ann Rheum Dis 1998;57:252–254.
  • Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754–63.
  • Xiao R, Yoshida N, Higashi Y et al. Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts. J Dermatol. 2011;38:345-53.
  • Yüksek J, Sezer E, Köseo lu D, et al. Scleredema treated with broad-band ultraviolet A phototherapy plus colchicine. Photodermatol Photoimmunol Photomed. 2010;6:257-60.
  • Ziswiler HR, Urech R, Balmer R. Clinical diagnosis compared to classification criteria in a cohort of 54 patients with systemic sclerosis and associated disorders Swiss Med Wkly. 2007;137:586-90.
Data source: Dialnet